Long-term survivors of hematopoietic cell transplantation (HCT) are at risk for loss of bone mineral density (BMD) and subsequent osteoporosis. There is a lack of clear guidelines for the screening, prevention and treatment of bone loss after HCT. We reviewed the prevailing literature and provide guidelines developed by our center for the screening and management of this complication. Bone loss occurs predominantly within the first 6-12 months after autologous and allogeneic HCT. Recovery first occurs in the lumbar spine and is followed by a slower recovery of BMD in the femoral neck. BMD may not return to baseline levels in patients with continuing exposure to corticosteroids and calcineurin inhibitors. All HCT recipients should be advised general interventions to reduce fracture risk including adequate intake of calcium and vitamin D. We recommend screening all adult allogeneic and autologous HCT recipients with dualenergy X-ray absorptiometry 1 year after transplantation. Patients at high risk for bone loss (for example, patients receiving X5 mg of prednisone equivalent daily for 43 months) can be screened earlier (for example, 3-6 months after HCT). Where indicated, bisphosphonates or other anti-resorptive agents (for example, calcitonin) can be used for prevention or treatment of osteoporosis in adult HCT recipients. Pediatric HCT recipients should be referred to a pediatric endocrinologist for evaluation and treatment of bone loss. There remain several areas of uncertainty that need further research in adult and pediatric HCT recipients, such as the optimal timing and frequency of screening for loss of bone mineral density, relationship of bone loss with risk of fractures, selection of appropriate patients for pharmacologic therapy, and optimal dosing schedule and duration of therapy with anti-resorptive agents.
Introduction
Advances in transplantation techniques and supportive care practices have led to an enlarging population of longterm survivors of hematopoietic cell transplantation (HCT), who are at risk for developing late complications of transplantation. One such late complication is loss of bone mass, which can eventually lead to osteoporosis with its consequent increase in bone fragility and risk of fractures. Although there has recently been increased interest and research in bone loss after HCT, screening, assessment and treatment of this complication remains controversial. This article reviews the diagnosis and management of osteopenia and osteoporosis after HCT and suggests guidelines that our center has developed for long-term follow-up.
Diagnosis of osteoporosis and bone loss
The diagnosis of osteoporosis is determined by measurement of bone mineral density (BMD) using dual-energy X-ray absorptiometry (DXA). Scores are reported as grams of mineral per square centimeter and then standardized against normal population means. BMD at various sites is compared with either the mean BMD of an age/gender/ ethnicity-matched population (Z-score) or the mean BMD of a normal, young adult population of the same gender (T-score). Expression of these scores differs by patient age and menopausal status. The T-score is the accepted expression of BMD in postmenopausal women and men X50 years. For children, adolescents, young adults and men up to the age of 49 years, Z-scores are the preferred method of reporting BMD. Scores are expressed as s.d. from these norms and are characterized in adults as being normal (T-score being XÀ1.0), low bone mass or 'osteopenia' (T-score between À1.0 and À2.5) or osteoporosis (T-score pÀ2.5).
1,2 In children, scores are expressed as being normal (Z-score 4À2.0) or indicating low BMD (Z-score pÀ2). 3 The term 'osteoporosis' is used in pediatrics only if there is a Z-score pÀ2 and a clinically significant fracture history defined as a long bone fracture of the lower extremities, a vertebral compression fracture, or two or more long-bone fractures of the upper extremities. 4 The risk of fracture increases roughly twofold for each s.d. decrease in BMD. 5 Accepted sites of measurement in adults include the femoral neck, total hip and spine, and is done over at least two vertebral bodies in the posterior-anterior projection. The lowest score is used for diagnosis of osteoporosis. The radius can also be used if the hip or spine cannot be measured, although its relationship with fracture risk has not been well characterized. Overall, hip is the best predictor of fracture risk. Accepted sites of measurement in pediatrics include the total body less head and lumbar spine. 3 The definition of osteopenia and osteoporosis is based on BMD measurement only. However, the estimation of risk of fractures has to take into account BMD (T-score or Z-score) along with a number of other factors. BMD alone is not predictive of fracture risk and fractures can occur with BMD scores that do not meet the definition of osteoporosis. 6, 7 Osteoporosis, therefore, may be diagnosed clinically in the presence of a fragility fracture irrespective of the T-score. The World Health Organization has proposed an instrument to calculate the 'fracture risk'-the Fracture Risk Assessment Tool (FRAX). This instrument allows the calculation of a patient's 10-year risk of major fracture and takes into account BMD and other risk factors for fractures (Table 1) . 8 This tool is widely used in the non-transplant setting to evaluate the need for therapy for osteoporosis, but there have been no studies in HCT recipients to validate or understand its utility.
Mechanisms of bone loss after HCT
The pathogenesis of bone disease after HCT has been comprehensively reviewed by Weilbaecher. 9 Osteoporosis occurs due to uncoupling of bone formation and bone resorption, resulting in overactive osteoclastic bone resorption and underactive bone osteoblastic formation. The mechanisms of transplantation-related osteoporosis are multifactorial and incompletely understood, and bone loss occurs through a complex interaction of pre-, peri-and post-HCT factors (Table 2) . These factors cause dysregulation of various hormones and cytokines that are involved in bone remodeling (for example, insulin-like growth factor-1, transforming growth factor b and bone morphogenic proteins) and cause an increase in bone resorption. 9 Other important mediators of osteoclast differentiation and function are two cytokines belonging to the TNF family: the receptor activator of nuclear factor-kappa B (RANK) ligand and osteoprotegerin (OPG).
9,10 RANK ligand is expressed on the surface of osteoblasts and binds to RANK on the cell surface of osteoclasts to promote their differentiation and activity. OPG inhibits this interaction and decreases the survival of osteoclasts. Normal bone health requires a balance between the RANK ligand and OPG interaction, and an increase in the RANK ligand-OPG ratio has been implicated in the pathogenesis of non-transplant osteoporosis. 10 An important factor that modulates this interaction is estrogen, which limits the release of RANK ligand from osteoblasts. Loss of estrogen after menopause leads to a significant increase in RANK ligand expression with a resultant imbalance of the RANK ligand-OPG interaction, and stimulation of osteoclasts and bone loss. A high-affinity MoAb targeted against RANK-ligand, denosumab, is currently under development for the treatment of osteoporosis. The mechanisms of posttransplantation bone loss in children are different and result from decrease in both bone formation and resorption leading to an adynamic bone state. Osteoporosis and bone loss after allogeneic HCT in adults
11
The incidence of osteoporosis and osteopenia before allogeneic transplantation has been reported to range from 0 to 29 and 3 to 43%, respectively. [12] [13] [14] [15] [16] [17] The temporal sequence of bone loss after allogeneic HCT has been summarized in a review by Tauchmanova`et al. 18 Bone loss occurs within the first 6 to 12 months after HCT at all sites. Recovery then begins, first noted by increase in BMD of the lumbar spine and is followed by a slower recovery of BMD in the femoral neck, where bone loss can persist for years. BMD may not return to baseline levels among patients with continuing exposure to risk factors such as corticosteroids and calcineurin inhibitors.
Studies of anti-resorptive therapy in allogeneic HCT recipients are summarized in Table 3 . To date, five randomized trials of bisphosphonates and/or hormonal agents in addition to supplementation of calcium and Vitamin D have been published. [14] [15] [16] 19, 20 Five other nonrandomized studies of pharmacological therapy were also found in the literature. 12, [21] [22] [23] [24] Their findings include:
(1) Bisphosphonates can lead to improvement in BMD in the lumbar spine and the femoral neck over the first few years after HCT. 14, 15, [19] [20] [21] [22] 24 There is inadequate data to suggest the superiority of a specific agent or dosing schedule over another among HCT recipients. (2) In one study, calcium supplementation alone was not effective in preventing bone loss after HCT.
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(3) Hormone replacement therapy along with calcium and vitamin D has not been consistently shown to prevent loss of BMD in all patients. 12, 14, 19, 20, 23 (4) The duration of therapy for prevention of bone loss is unclear, although the majority of studies have treated patients for 12 months. Grigg et al. 19 have shown persistence of bone loss after discontinuation of pamidronate, indicating that close follow-up is likely needed after treatment based on risk factors.
Overall, the published experience with prevention and treatment of bone loss and osteoporosis after allogeneic HCT is limited to studies with small numbers of patients. Studies have used varying definitions of osteoporosis and osteopenia. The correlation of osteoporosis with fracture risk in this population is also unclear. Savani et al. 25 reported no fractures in a group of long-term allogeneic HCT survivors (median age 35 years, median follow-up 78 months) who had undergone BMD evaluation. Osteopenia was present in 42% of patients and osteoporosis in 32% and the majority of patients had not received prophylactic bisphosphonates.
Osteoporosis and bone loss after autologous HCT in adults
Compared with allogeneic HCT, the effect of autologous HCT on bone health has been less well characterized, and studies again have the limitations of small sample size and inconsistent definitions of bone loss. The incidence of 
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Ca (12) vs Ca/Calcitonin(10) vs no therapy (22) 12 mo BMD loss not prevented with either therapy [27] [28] [29] BMD loss at the spine recovers sooner after HCT compared with the femoral neck, which may persist for 2-4 years after HCT. 27, 29 Recovery of BMD was directly related to age in one series, 29 whereas age, gender and stem cell source had no significant impact on BMD in another analysis. 27 More recently, Ria et al. 28 published a prospective series of 180 autologous HCT patients whose BMD was followed for a median of 5.4 years and compared them with 20 patients who received only chemotherapy. As can be expected, older age was associated with greater BMD loss. However, BMD loss was also seen in younger patients; 35% of patients aged 25-35 years and 77% of those aged X55 years had T scores of oÀ1. BMD loss was greatest in the first year after HCT, with the incidence of osteopenia/osteoporosis reaching 65% in the HCT population vs 5% in the control population. Recovery was noted in the spine and wrist beginning 2 years after HCT with continued maintenance of this BMD thereafter. In contrast, Keilholz et al. found no significant differences in BMD among 29 autologous HCT recipients evaluated X3 years after HCT and their age-and gender-matched controls. 30 However, the majority of women in this study had been on hormone replacement therapy.
As with allogeneic HCT, no series has demonstrated an increase in the risk of fracture in autologous HCT recipients. Moreover, no therapeutic trial has specifically investigated prevention or treatment of osteopenia or osteoporosis specifically in this population. Castelo-Branco et al.
12 evaluated hormone replacement therapy in a combined cohort of eight autologous and five allogeneic female HCT patients, 70% of whom had evidence of osteoporosis or osteopenia. They were able to demonstrate that all patients had increased their lumbar spine BMD over the course of 12 months of treatment.
Areas of uncertainty and future research
When and how often to screen for osteoporosis? The appropriate time to initiate screening for osteoporosis is not known and has not been addressed by the prevailing literature. Some centers screen patients pre-transplantation whereas others may wait until 1 year or later posttransplant to initiate screening for osteoporosis. Published late-effects guidelines for HCT recipients recommend bone density testing starting at 1 year post-transplant among women and in patients with prolonged corticosteroid or calcineurin inhibitor exposure. 8 Screening before HCT would identify patients with preexisting osteopenia and osteoporosis and these patients may benefit from early interventions to prevent and reverse bone loss from transplant. The incidence of pre-existing osteopenia and osteoporosis among HCT recipients needs to be better characterized, but is overall relatively low. 23, 27, 31, 32 Furthermore, given the high rates of early post-transplant mortality because of complications and relapse, the cost-effectiveness of a pre-HCT screening approach needs to be evaluated further. Initiation of screening late post-transplantation has the disadvantage of delaying interventions in patients who may be at risk for severe bone loss, especially patients on high doses of corticosteroids for GVHD. 23 Until there is better evidence for the optimal timing for screening, waiting till 1 year after HCT to initiate screening with DXA for osteoporosis is a prudent approach for most patients. Patients who are on or are expected to remain on corticosteroids for a prolonged period of time (X5 mg of prednisone equivalent daily for 43 months) can be screened earlier (for example, 3-6 months after HCT).
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Is intervention needed for all patients?
Despite the observation that both autologous and allogeneic HCT recipients experience bone loss after transplantation, this decrease in BMD has not been definitively shown to correlate with fracture risk in the first few years after HCT. Whether early pharmacological intervention impacts long-term fracture risk in HCT survivors, especially among those who have not received corticosteroids, is not known. The risks of bone loss and fracture may be different among autologous and allogeneic HCT recipients and whether each requires a different strategy for prevention and treatment of bone loss needs further investigation. Judicious selection of appropriate patients for therapy is necessary. Therapy with bisphosphonates, the most frequently prescribed agents for osteoporosis, can be associated with rare but serious adverse events such as osteonecrosis of the jaw and esophageal ulceration. [33] [34] [35] Based on studies carried out in the non-HCT setting, there is good evidence to support drug therapy for osteopenia and osteoporosis among adults receiving corticosteroids. 34, 36, 37 An estimated 50% of adults taking corticosteroids for 46 months develop secondary osteoporosis, among whom up to half suffer a fracture. 38 Fractures occur at higher BMD levels compared with patients with osteoporosis who have not received corticosteroids. There is no safe minimum dose or duration of corticosteroid exposure and higher doses incrementally increase the fracture risk. 38, 39 Based on the total cumulative dose exposure, fracture risks return to baseline 6-18 months after discontinuation of corticosteroid therapy. 38, 39 Guidelines recommend screening BMD assessment in both adults and children receiving long-term corticosteroid therapy (prednisone equivalent of X5 mg/day). 4, 34, 36 Annual or biannual BMD measurement is recommended for patients with normal BMD, but continuing exposure to corticosteroids and treatment with bisphosphonates or calcitonin is recommended for adults with a T-score o-1 to -1.5.
Until better data are available about the contribution of HCT to fracture risk among transplant recipients with osteoporosis who are not receiving corticosteroids, we recommend treatment with a bisphosphonate or another agent (for example, calcitonin) for adults with a T-score pÀ2.5 (Table 4 ). In patients with osteopenia (T-score between À1.0 and À2.5), decision to treat should be based on the overall fracture risk assessment, which includes nontransplant risk factors. The World Health Organization FRAX tool (http://www.shef.ac.uk/FRAX/) is a useful instrument for such assessments and could be used in future clinical trials to guide treatment decisions. 40, 41 What is the optimal drug and duration for anti-resorptive therapy? There is insufficient evidence from clinical trials in the non-transplant setting (for example, post-menopausal osteoporosis) to suggest the superiority of one bisphosphonate over another or of bisphosphonates over other agents (for example, calcitonin). 33, 34 However, in a recent study, patients with glucocorticoid induced osteoporosis at high risk for fracture had a greater increase in BMD and a lower rate of vertebral fractures with recombinant human parathyroid hormone teriparatide compared with alendronate. 42 The appropriate duration of anti-resorptive therapy is also not clear and clinical trials have studied 3 months to 60 months of therapy; however, most studies indicate that at least 1-2 years of therapy with bisphosphonates is needed to achieve a significant reduction in fracture risk. 33, 34, 36 Bisphosphonates are the most frequently studied antiresorptive agents for transplantation-associated bone loss and osteoporosis (Table 3 ). There are no data to support the use of one bisphosphonate over another among HCT recipients for the prevention or treatment of osteoporosis. Choice of therapy should consider patient preference (for example, route of administration and dosage frequency), ability to tolerate a drug (for example, underlying renal insufficiency or gastrointestinal symptoms), risk factors for toxicity (for example, renal failure or esophageal ulcerations) and reimbursement (Table 4) . Patients who cannot tolerate or have contraindication to bisphosphonates can be treated with an alternative agent such as calcitonin, raloxifene or teriparatide. The optimal duration of antiresorptive therapy for prevention or treatment of transplantation-associated osteoporosis is not known. At least 1-2 years of therapy is needed to recover bone loss and reduce fracture risk; further therapy should be guided by risk factors for fracture and BMD assessments. Patients with steroid-dependent chronic GVHD may need a longer duration of anti-resorptive therapy.
Osteoporosis and bone loss in pediatric HCT recipients
Peak bone mass is achieved by early adulthood (second or third decades), with subsequent progressive loss during adult life. Patients who do not reach the optimal BMD during childhood, particularly during adolescence, may be more likely to suffer from osteoporotic fractures later in life because of a low peak BMD. 43 Therefore, it is critical to address bone health in pediatric populations in order to optimize the peak bone mass achieved and subsequently reduce the risk of fracture in adulthood. Sequelae from treatment with HCT during childhood may interrupt this critical period of bone acquisition.
Summary of pediatric literature on bone loss after HCT Bone deficits after pediatric HCT have not yet been fully characterized; few studies have reported specifically on pediatric populations and a standardized approach to analysis of bone density data has not been used. Lower BMD compared with healthy controls during and in shortterm follow-up after non-HCT treatment of childhood cancer has been reported. [44] [45] [46] In a study of 44 children treated with HCT for cancer, the baseline prevalence of osteopenia/osteoporosis was reported to be 48% in acute lymphoblastic leukemia, 6% in solid tumors and 67% in aplastic anemia. 47 Petryk et al. 11 reported an increase in the prevalence of osteopenia (Z-score oÀ1 and 4À2) from 18% before HCT to 33% at 1 year after HCT; low BMD (Z-score pÀ2) increased from 16 to 19%. Beyond 1 year after HCT in children, bone deficits may be greater compared with adult recipients. For example, 1-10 years after HCT Bhatia et al. 48 found lower BMD Z-scores in pediatric compared with adult HCT recipients, pediatric total body BMD Z-scores were 5% lower than controls, and a younger age at HCT correlated with lower BMD Z-scores. Controls were matched on age, gender, weight and ethnic background; height, which has since been shown to influence BMD determined by DXA in pediatric populations, was not included in the analysis. In contrast, after adjusting for height, Nysom et al. 49 reported no difference in mean whole-body bone mineral content and BMD in children with leukemia or lymphoma treated with HCT; unadjusted Z-scores were 0.8 and 0.5 s.d. less than those of healthy controls 4-13 years after treatment, respectively. Using an estimation of volumetric lumbar spine BMD, Daniels et al. found significantly lower Z-scores (mean ranged from -0.8 to -0.9 for hip, femur, lumbar spine and whole body) 1-12 years after pediatric HCT compared with healthy controls. 50 In children with thalassemia major, the prevalence of a BMD Z-score of oÀ2.5 was 36% in the lumbar spine and 6% in the hip; this was lower than those not treated with HCT (62 and 35%, respectively), although these scores were not adjusted for height. 51 Using quantitative computed tomography instead of DXA, which provides a volumetric assessment of BMD, Kaste et al. 52 reported that 9 of 43 (21%) children had low BMD in the lumbar spine 1-10 years after HCT; these deficits were not associated with gender, age at HCT, time since HCT, conditioning regimen, diagnosis or endocrine dysfunction. The contradictory results are at least in part due to small sample sizes, which limit the power to precisely determine the degree of bone deficit or to identify subsets of children at high risk for developing bone deficits after HCT. Overall, these studies, which primarily evaluated bone health using DXA, suggest that mild bone deficits are present in children 1-10 years after HCT. However, the data are inconsistent, partly because of limitations of DXA, which cannot account for bone size or shape, particularly in children in whom bone size is continually changing. This can result in a falsely decreased BMD in children who are small for their age simply because of small bone size. [53] [54] [55] [56] Given the high prevalence of growth impairment after pediatric HCT, 1, [57] [58] [59] and this limitation of DXA when interpreting BMD in the presence of short stature in children, it is unknown if these bone deficits determined by DXA are clinically important, or are simply due to an underestimation of BMD in the presence of small bone size. Techniques such as quantitative computed tomography (as used by Kaste et al.
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) or peripheral quantitative computed tomography provide more accurate assessments of BMD in children compared with DXA. Larger prospective studies, adjusting for bone size, are needed to determine whether bone deficits do indeed persist after pediatric HCT or whether pediatric bone is ultimately able to recover from injury during the HCT process.
Recommendations for screening and treatment of bone loss in pediatric HCT recipients We are unaware of any published data on the persistence of bone deficits into adulthood, prevalence of fracture, or impact on the timing or severity of adult osteoporosis after pediatric HCT. Research addressing these areas will guide decisions on when, if at all, to intervene with medical therapies for improving bone health. Until these data are available, we recommend optimizing pediatric bone health through ensuring adequate calcium and vitamin D intake, encouraging activity as tolerated, annual screening for endocrine dysfunction and clinical monitoring of BMD by DXA in children as per the International Society of Clinical Densitometry guidelines. 60 The decision on when to intervene with pharmacological treatments to prevent or treat bone disease in children after HCT should be made in consultation with a pediatric endocrinologist. No standard treatment guidelines for preventing or treating pediatric bone disease after HCT are possible at this time because of there being very limited published data.
61,62

Summary of recommendations for prevention and treatment
Consensus guidelines from the CIBMTR, ASBMT and EBMT recommend screening with dual photon densitometry at 1 year after HCT for adult women and for any patient who has received prolonged treatment with corticosteroids or calcineurin inhibitors. 8 A baseline bone density scan is recommended by the Children's Oncology Group guidelines at 2 years after completion of therapy. 62, 63 Based on the results of a comprehensive literature review and opinion from experts in adult and pediatric transplantation and endocrinology, our program has developed more comprehensive guidelines for prevention and treatment of bone loss and osteoporosis after HCT (Figure 1 ). We recognize that individual patient circumstances may vary and emphasize that, in addition to BMD measurement, specific patient risk factors for fractures should be considered in guiding decisions for prevention and treatment of osteoporosis. Moreover, these guidelines are most applicable to adult HCT recipients; pediatric HCT recipients should be treated in consultation with a pediatric endocrinologist.
All adult HCT recipients should be advised general interventions to reduce fracture risk, such as adequate intake of calcium (at least 1200 mg per day) and vitamin D (800-1000 IU per day), regular weight-bearing and musclestrengthening exercises, avoiding tobacco and excessive alcohol use and preventing falls. Measurement of blood 25-hydroxy vitamin D levels should be considered in adult and pediatric HCT recipients and higher doses of vitamin D may be required in patients with levels o30 ng/mL. 64 In
HCT recipients who need drug therapy for prevention or treatment of osteoporosis, bisphosphonates or other antiresorptive agents can be used (Table 4 ). In our experience, patients tend to prefer oral bisphosphonates with weekly or monthly dosing frequency (for example, alendronate, ibandronate and risedronate) and the majority of patients are able to tolerate these agents well, especially with respect to upper gastrointestinal side effects. Zoledronic acid with once a year dosing for treatment and once every 2-years dosing for prevention of osteoporosis is an attractive option, which has not been studied in HCT recipients. The risk of osteonecrosis of the jaw has been reported to be higher with zoledronic acid compared with oral bisphosphonates, although this complication has been primarily seen among patients receiving frequent doses for multiple myeloma or metastatic breast cancer. 35 Calcitonin is an alternative agent and has a very favorable side effect profile. Teriparatide is also approved for the treatment of osteoporosis in general and is well tolerated. It has been associated with an increase in the incidence of osteosarcoma in rats when used in high doses over a long period of time and is therefore recommended for a maximum of 2 years and should be avoided in patients who have received TBI or radiation to the bone and in pediatric patients with open growth plates. 65 More research is needed to better define the optimal timing and frequency of screening for loss of BMD, relationship of bone loss with risk of fractures, selection of appropriate patients for pharmacological therapy, and optimal dosing schedule and duration of therapy with antiresorptive agents. 
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